Ambient

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization signal (NLS) on its N terminal end, and an EGFP and a 6x(His) sequence on the C terminal end. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a highly stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. When Cas9 is expressed with an NLS sequence, the Cas9 RNP complex can localize to the nucleus immediately upon entering the cell. There is no requirement for in vivo transcription or translation, which improves the efficiency of this method over plasmid-based systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP tag can be used as a reporter for tracking or sorting transfected cells, which enables enrichment of cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications. 

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

– DNA-free: no external DNA added to system
– High cleavage efficiency: NLS ensures the efficient entry of the Cas9 protein into nuclei
– Low off target effects: transient expression of Cas9 nuclease improves specificity of cleavage
– Time-saving: no need for transcription and translation
– Reduced labor: enrich cell populations for desired genome edits via EGFP-based FACS. The C-terminal His-tag increases the choice of detection methods for the fusion protein.

Applications

– Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.
– In vivo gene editing when combined with a specific gRNA by electroporation or injection.
– Enrichment of cell populations for desired genome edits via EGFP-based FACS.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization signal (NLS) on its N terminal end, and an EGFP and a 6x(His) sequence on the C terminal end. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a highly stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. When Cas9 is expressed with an NLS sequence, the Cas9 RNP complex can localize to the nucleus immediately upon entering the cell. There is no requirement for in vivo transcription or translation, which improves the efficiency of this method over plasmid-based systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP tag can be used as a reporter for tracking or sorting transfected cells, which enables enrichment of cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications. 

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

– DNA-free: no external DNA added to system
– High cleavage efficiency: NLS ensures the efficient entry of the Cas9 protein into nuclei
– Low off target effects: transient expression of Cas9 nuclease improves specificity of cleavage
– Time-saving: no need for transcription and translation
– Reduced labor: enrich cell populations for desired genome edits via EGFP-based FACS. The C-terminal His-tag increases the choice of detection methods for the fusion protein.

Applications

– Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.
– In vivo gene editing when combined with a specific gRNA by electroporation or injection.
– Enrichment of cell populations for desired genome edits via EGFP-based FACS.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization sequence (NLS) on its N terminal and EGFP on the C terminal. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP can be used as a reporter for tracking or sorting transfected cells, which enables the possibility of enriching cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications.

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

– In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization sequence (NLS) on its N terminal and EGFP on the C terminal. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP can be used as a reporter for tracking or sorting transfected cells, which enables the possibility of enriching cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications.

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

– In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-EGFP is a fusion protein developed by GenScript. It contains a nuclear localization sequence (NLS) on its N terminal and EGFP on the C terminal. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cells minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). The EGFP can be used as a reporter for tracking or sorting transfected cells, which enables the possibility of enriching cell populations for desired genome edits via fluorescence activated cell sorting (FACS). It significantly reduces the labor and cost associated with single cell cloning and genotyping in genome editing applications.

Product Source: GenCrispr NLS-Cas9-EGFP is produced by expression from an E. coli strain.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

-Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

– In vivo gene editing when combined with a specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a NLS-Cas9-NLS nuclease which contains a nuclear localization sequence (NLS) on both ends of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a nuclear localization signal (NLS) on both ends.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a NLS-Cas9-NLS nuclease which contains a nuclear localization sequence (NLS) on both ends of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a nuclear localization signal (NLS) on both ends.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a NLS-Cas9-NLS nuclease which contains a nuclear localization sequence (NLS) on both ends of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a nuclear localization signal (NLS) on both ends.

Key Features

-DNA-free: no external DNA added to system

-High cleavage efficiency: Double NLS ensures the efficient entry of Cas9 protein into nuclei

-Low off target: transient expression of Cas9 nuclease

Time-saving: no need for transcription and translation

Applications

-Screening for highly efficient and specific targeting gRNAs by in vitro DNA cleavage.

–In vivo gene editing when combined with a specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-NLS nuclease is the recombinant Streptococcus pyogenes Cas9 (wt) protein with a nucleic localization signal (NLS) on both N and C terminal, which can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher´s requirements (e.g. in vitro cleavage assay, RNP complex transfection, micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a double-ends nuclear localization signal (NLS).

Key features:

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

GenCrispr NLS-Cas9-NLS nuclease is the recombinant Streptococcus pyogenes Cas9 (wt) protein with a nucleic localization signal (NLS) on both N and C terminal, which can be used for genome editing by inducing site-specific DNA double stranded breaks. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system, which can localize to the nucleus immediately once entering the cell with the guide of the NLS. Compared with the mRNA or plasmid systems, transcription and translation processes are not required. This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. Our highly pure and active Cas9 nuclease meets all of the researcher´s requirements (e.g. in vitro cleavage assay, RNP complex transfection, micro injection).

Product Source: GenCrispr NLS-Cas9-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a double-ends nuclear localization signal (NLS).

Key features:

With this Cas9 Nuclease, you can:

1. Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
2. In vivo gene editing combined with specific gRNA by electroporation or injection.

Cas9 Nuclease NLS, S. pyogenes, is an RNA-guided endonuclease that catalyzes site-specific cleavage of double stranded DNA. The location of the break is within the target sequence 3 bases from the NGG PAM (Protospacer Adjacent Motif). The design of single guide RNA (sgRNA) is dependent on the target region close to the PAM site. Even if you pick a target sequence that fulfills all of the described requirements, sgRNA specificity and activity is unpredictable. Therefore, it is often recommended that multiple, different sgRNAs be designed to target a gene of interest. The GenCrispr sgRNA Screening Kit provides a simple, reliable, and rapid method for assessing sgRNA efficiency before cell transduction, allowing you to identify the highly effective CRISPR sgRNA.

T7 Endonuclease I (T7E1) recognizes and cleaves non-perfectly matched DNA, cruciform DNA structures, Holliday structures or junctions, hetero duplex DNA and more slowly, nicked double-stranded DNA. The cleavage site is at the first, second or third phosphodiester bond that is 5´ to the mismatch. The protein is the product of T7 gene 3. GenCrispr T7 Endonuclease I is a fusion protein produced from E.coli.

T7 Endonuclease I (T7E1) recognizes and cleaves non-perfectly matched DNA, cruciform DNA structures, Holliday structures or junctions, hetero duplex DNA and more slowly, nicked double-stranded DNA. The cleavage site is at the first, second or third phosphodiester bond that is 5´ to the mismatch. The protein is the product of T7 gene 3. GenCrispr T7 Endonuclease I is a fusion protein produced from E.coli.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

The
clustered regularly interspaced short palindromic repeats, known as CRISPR  systems are adaptive immune mechanisms commonly
present in archaea and bacteria. The CRISPR systems enable the host to specifically
target and cleave foreign nucleic acids thus targeting infectiousviruses and
plasmids. Recently, a type V CRISPR system has been identified in several
bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to
Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an
additional trans-activating crRNA (tracrRNA), and allow for targeting of
additional genomic regions by cleaveing the target DNA proceeded by a short
T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires
a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a
staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant
Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and
purified. The nuclease contains nuclear localization sequence (NLS) at the
C-terminus and 6× His-tag at the C-terminus.

GenCRISPR Cas13a (C2c2) Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as C2c2. This enzyme is a member of Type VI CRISPR family containing a single protein effector with two HEPN domains. The Cas13a exhibits two RNase activities. The first activity, a cis- sequence-specific RNA guided cleavage, activates the secondary RNase activity of the enzyme, a non-specific trans- ribonuclease activity. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity.

GenCRISPR Cas13a (C2c2) Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as C2c2. This enzyme is a member of Type VI CRISPR family containing a single protein effector with two HEPN domains. The Cas13a exhibits two RNase activities. The first activity, a cis- sequence-specific RNA guided cleavage, activates the secondary RNase activity of the enzyme, a non-specific trans- ribonuclease activity. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity.

GenCRISPR Cas13a (C2c2) Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as C2c2. This enzyme is a member of Type VI CRISPR family containing a single protein effector with two HEPN domains. The Cas13a exhibits two RNase activities. The first activity, a cis- sequence-specific RNA guided cleavage, activates the secondary RNase activity of the enzyme, a non-specific trans- ribonuclease activity. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity.

The GenCRISPR™
Cas9 v1.1 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Streptococcus
pyogenes with a biparticle nucleus localization signal (BPNLS) at both
N-terminal and C-terminal. It has been reported that BPNLS is able to improve
the gene editing efficiency.

The GenCRISPR™
Cas9 v1.1 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Streptococcus
pyogenes with a biparticle nucleus localization signal (BPNLS) at both
N-terminal and C-terminal. It has been reported that BPNLS is able to improve
the gene editing efficiency.

The GenCRISPR™
Cas9 v1.1 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Streptococcus
pyogenes with a biparticle nucleus localization signal (BPNLS) at both
N-terminal and C-terminal. It has been reported that BPNLS is able to improve
the gene editing efficiency.

The GenCRISPR™
Cas9 v1.2 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™ Cas9 v1.2 is a tag
free nuclease produced by expression in an E.
coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle
nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus
localization signal (nucleoplasmin NLS) at C-terminal. It has been reported
that BPNLS and nucleoplasmin NLS are able to improve the gene editing
efficiency. 

The GenCRISPR™
Cas9 v1.2 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™ Cas9 v1.2 is a tag
free nuclease produced by expression in an E.
coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle
nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus
localization signal (nucleoplasmin NLS) at C-terminal. It has been reported
that BPNLS and nucleoplasmin NLS are able to improve the gene editing
efficiency. 

The GenCRISPR™
Cas9 v1.2 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™ Cas9 v1.2 is a tag
free nuclease produced by expression in an E.
coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle
nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus
localization signal (nucleoplasmin NLS) at C-terminal. It has been reported
that BPNLS and nucleoplasmin NLS are able to improve the gene editing
efficiency. 

GenCRISPR™ ErCas12a Nuclease is an RNA-guided DNA endonuclease from Eubacterium rectale. It recognizes a T-rich protospacer adjacent motif (PAM) and results in a staggered DNA double-strand break (DSB). After the specific cleavage, Cas12a can also activate collateral cleavage activity towards adjacent non-specific ssDNA sequences. Hence, Cas12a nuclease is a good alternative for Cas9 in certain target DNA editing, and provides a novel strategy for DNA detection.

GenCRISPR™ ErCas12a Nuclease is an RNA-guided DNA endonuclease from Eubacterium rectale. It recognizes a T-rich protospacer adjacent motif (PAM) and results in a staggered DNA double-strand break (DSB). After the specific cleavage, Cas12a can also activate collateral cleavage activity towards adjacent non-specific ssDNA sequences. Hence, Cas12a nuclease is a good alternative for Cas9 in certain target DNA editing, and provides a novel strategy for DNA detection.

GenCRISPR™ ErCas12a Nuclease is an RNA-guided DNA endonuclease from Eubacterium rectale. It recognizes a T-rich protospacer adjacent motif (PAM) and results in a staggered DNA double-strand break (DSB). After the specific cleavage, Cas12a can also activate collateral cleavage activity towards adjacent non-specific ssDNA sequences. Hence, Cas12a nuclease is a good alternative for Cas9 in certain target DNA editing, and provides a novel strategy for DNA detection.

GenCRISPR™ LbCas12a Nuclease is an RNA-guided DNA endonuclease from Lachnospiraceae bacterium. Cas12-family enzymes exhibit two DNase activity modes; besides crRNA-guided cis-cleavage of cDNA targets, these nucleases also catalyze trans-cleavage of non-target ssDNA substrates introduced by target DNA, which has been exploited to develop sensitive technologies for nucleic acid detection.

GenCRISPR™ LbCas12a Nuclease is an RNA-guided DNA endonuclease from Lachnospiraceae bacterium. Cas12-family enzymes exhibit two DNase activity modes; besides crRNA-guided cis-cleavage of cDNA targets, these nucleases also catalyze trans-cleavage of non-target ssDNA substrates introduced by target DNA, which has been exploited to develop sensitive technologies for nucleic acid detection.

GenCRISPR™ LbCas12a Nuclease is an RNA-guided DNA endonuclease from Lachnospiraceae bacterium. Cas12-family enzymes exhibit two DNase activity modes; besides crRNA-guided cis-cleavage of cDNA targets, these nucleases also catalyze trans-cleavage of non-target ssDNA substrates introduced by target DNA, which has been exploited to develop sensitive technologies for nucleic acid detection.

GenCRISPR™ LbuCas13a Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as LbuC2c2. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity. Recently, Cas13a has been leveraged as a diagnostic nucleic acid detection tool.

GenCRISPR™ LbuCas13a Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as LbuC2c2. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity. Recently, Cas13a has been leveraged as a diagnostic nucleic acid detection tool.

GenCRISPR™ LbuCas13a Nuclease is an RNA-guided, RNA-targeting CRISPR enzyme, commonly referred to as LbuC2c2. This Cas13a protein can be applied to detect single RNA molecules with proven high specificity. Recently, Cas13a has been leveraged as a diagnostic nucleic acid detection tool.

The GenCRISPR™
SaCas9 2NLS Nuclease can be formed with the guide RNA into a ribonucleoprotien
(RNP) complex. The use of an RNP complex to perform gene editing has been shown
to reduce the challenges encountered with other CRISPR gene editing techniques
such as viral and plasmid delivery. Challenges include off-target effects, cell
viability and transcription/translational challenges. The SaCas9 recognizes an
NNGRRT protospacer adjacent motif (PAM) and cleaves target DNA at high
efficiency with a variety of guide RNA (gRNA) spacer lengths.

GenCRISPR™ SaCas9 2NLS
Nuclease is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Staphylococcus
aureus with a nuclear localization signal at both N-terminal and C-terminal.The
small size of the nuclease facilitates enhanced in vivo delivery for genome
editing in various organisms.

The GenCRISPR™
SaCas9 2NLS Nuclease can be formed with the guide RNA into a ribonucleoprotien
(RNP) complex. The use of an RNP complex to perform gene editing has been shown
to reduce the challenges encountered with other CRISPR gene editing techniques
such as viral and plasmid delivery. Challenges include off-target effects, cell
viability and transcription/translational challenges. The SaCas9 recognizes an
NNGRRT protospacer adjacent motif (PAM) and cleaves target DNA at high
efficiency with a variety of guide RNA (gRNA) spacer lengths.

GenCRISPR™ SaCas9 2NLS
Nuclease is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Staphylococcus
aureus with a nuclear localization signal at both N-terminal and C-terminal.The
small size of the nuclease facilitates enhanced in vivo delivery for genome
editing in various organisms.

The GenCRISPR™
SaCas9 2NLS Nuclease can be formed with the guide RNA into a ribonucleoprotien
(RNP) complex. The use of an RNP complex to perform gene editing has been shown
to reduce the challenges encountered with other CRISPR gene editing techniques
such as viral and plasmid delivery. Challenges include off-target effects, cell
viability and transcription/translational challenges. The SaCas9 recognizes an
NNGRRT protospacer adjacent motif (PAM) and cleaves target DNA at high
efficiency with a variety of guide RNA (gRNA) spacer lengths.

GenCRISPR™ SaCas9 2NLS
Nuclease is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid
encoding the Cas9 gene from Staphylococcus
aureus with a nuclear localization signal at both N-terminal and C-terminal.The
small size of the nuclease facilitates enhanced in vivo delivery for genome
editing in various organisms.

The product is specific for Staphylococcus aureus CRISPR/Cas9. This antibody binds with recombinant Staphylococcus aureus CRISPR/Cas9 protein in ELISA and Endogenous overexpressed Staphylococcus aureus CRISPR/Cas9 in immunofluorescence, western blot, immunoprecipitation.

The product is specific for Staphylococcus aureus CRISPR/Cas9. This antibody binds with recombinant Staphylococcus aureus CRISPR/Cas9 protein in ELISA and Endogenous overexpressed Staphylococcus aureus CRISPR/Cas9 in immunofluorescence, western blot.

The product is specific for Streptococcus pyogenes CRISPR/Cas9. This antibody binds with recombinant Streptococcus pyogenes CRISPR/Cas9 protein in ELISA and Endogenous overexpressed Streptococcus pyogenes CRISPR/Cas9 in immunofluorescence, western blot.

The product is specific for Streptococcus pyogenes CRISPR/Cas9. This antibody binds with recombinant Streptococcus pyogenes CRISPR/Cas9 protein in ELISA and Endogenous overexpressed Streptococcus pyogenes CRISPR/Cas9 in immunofluorescence, western blot.

GenCRISPR™ Ultra eSpCas9-2NLS-basic GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

GenCRISPR™ Ultra eSpCas9-2NLS-basic GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

GenCRISPR™ Ultra eSpCas9-2NLS-basic GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

GenCRISPR™ Ultra eSpCas9-2NLS-GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

GenCRISPR™ Ultra eSpCas9-2NLS-GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.

The GenCRISPR™
Ultra eSpCas9 product line provides customers with a selection of research use,
basic GMP and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with
the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex
to perform gene editing has been shown to reduce the challenges encountered
with other CRISPR gene editing techniques such as viral and plasmid delivery.
Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Ultra eSpCas9-2NLS is a mutant form of Cas9 nuclease and is produced by
expression in an E. coli strain
carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with double-ended nuclear localization
signal (NLS). GenCRISPR™ Ultra eSpCas9-2NLS delivers higher fidelity and less
off-target activity than wild-type SpCas9 nuclease.

The GenCRISPR™
Ultra eSpCas9 product line provides customers with a selection of research use,
basic GMP and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with
the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex
to perform gene editing has been shown to reduce the challenges encountered
with other CRISPR gene editing techniques such as viral and plasmid delivery.
Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Ultra eSpCas9-2NLS is a mutant form of Cas9 nuclease and is produced by
expression in an E. coli strain
carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with double-ended nuclear localization
signal (NLS). GenCRISPR™ Ultra eSpCas9-2NLS delivers higher fidelity and less
off-target activity than wild-type SpCas9 nuclease.

The GenCRISPR™
Ultra eSpCas9 product line provides customers with a selection of research use,
basic GMP and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with
the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex
to perform gene editing has been shown to reduce the challenges encountered
with other CRISPR gene editing techniques such as viral and plasmid delivery.
Challenges include off-target effects, cell viability and transcription/translational
challenges.

GenCRISPR™
Ultra eSpCas9-2NLS is a mutant form of Cas9 nuclease and is produced by
expression in an E. coli strain
carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with double-ended nuclear localization
signal (NLS). GenCRISPR™ Ultra eSpCas9-2NLS delivers higher fidelity and less
off-target activity than wild-type SpCas9 nuclease.